BioSpace News Archive

McKesson Corporation announced the final exchange ratio of 11.4086-for-one in connection with its previously announced offer to its stockholders to exchange their shares of McKesson common stock for shares of PF2 SpinCo, Inc. common stock.

LifeSci Acquisition Corp. (NASDAQ: LSACU), a blank check company targeting the biopharma, medical technology, digital health and healthcare services sectors, announced today that it priced its initial public offering of 6,000,000 units at $10.00 per unit.

Nine abstracts accepted, including long-term data and subgroup analyses from the Phase 3 PREVENT clinical trial evaluating SOLIRIS® (eculizumab) for the treatment of neuromyelitis optica spectrum disorder (NMOSD)

Pacific Biosciences of California, Inc. announced that industry veteran Christian Henry has been appointed to serve as Chairman of its Board of Directors.

TearLab Corporation (OTCQB: TEAR) (“TearLab” or the “Company”) today reported its consolidated financial results for the fourth quarter and twelve months ended December 31, 2019

Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, cardiovascular disease, announces financial results for the three and twelve months ended December 31, 2019.

US-based supply chain mitigates coronavirus-related disruption risks

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its fourth quarter and full year 2019 financial results on Thursday, March 12, 2020.

PsiOxus® Therapeutics, Ltd. (PsiOxus), the gene therapy for cancer company, today announced that it has started a clinical trial with NG-641, a four transgene tumor-microenvironment modifying cancer gene therapy, to cancer patients.

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced today that data from the interim analysis of Piclidenoson in its Phase III clinical study is expected to be released during Q4 2020.